Skip to main content
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. — Investor Relations & Filings

Ticker · OTLK ISIN · US69012T3059 LEI · 5493007AWUJ6HPMCBH11 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2026-06-01 Proxy Solicitation & In…
Country US United States of America
Listing US OTLK

About Outlook Therapeutics, Inc.

https://outlooktherapeutics.com/

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapies for ophthalmic indications. The company's lead product candidate is ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). If approved in the United States, it would be the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. The therapy, under the brand name LYTENAVA™ (bevacizumab gamma), has received Marketing Authorization from the European Commission and the UK's MHRA for the treatment of wet AMD. The monoclonal antibody works by inhibiting vascular endothelial growth factor (VEGF).

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-06-01 English
DEF 14A
Proxy Solicitation & Information Statement
2026-06-01 English
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is a Current Report on Form 8-K filed with the SEC. It announces an event (resubmission of a BLA and attaches a press release as an exhibit) rather than providing full financial statements, earnings highlights, or management discussion. It does not match any more specific category (e.g., earnings release, annual report, proxy statement), so it falls under the general Regulatory Filings category (RNS).
2026-06-01 English
FORM 8-K
Capital/Financing Update Classification · 91% confidence The document is an SEC Form 8-K current report in which Outlook Therapeutics, Inc. discloses a registered direct offering of 8,539,709 shares of common stock pursuant to a securities purchase agreement and related registration statement. This is a financing activity — specifically a capital raise — and therefore falls under our “Capital/Financing Update” category.
2026-05-29 English
424B5
Share Issue/Capital Change Classification · 85% confidence The document is a Form 424B5 prospectus supplement relating to an offering of 8.5 million new shares of common stock, detailing terms of the share issuance and warrant amendments in connection with the fundraising. It is not an annual or interim report, audit, or earnings release, but a legal offering document for new equity issuance—this falls under ‘Share Issue/Capital Change’ (SHA).
2026-05-29 English
FORM 8-K
Capital/Financing Update Classification · 92% confidence The document is a Form 8-K current report disclosing a registered direct offering (8,539,709 shares priced-at-the-market raising ~$5.0 million) and a warrant amendment, which are financing activities. This falls squarely under capital/financing updates rather than a general regulatory notice or share issuance announcement alone. Therefore, the most appropriate category is Capital/Financing Update (CAP).
2026-05-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.